Tarnoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles:: In vitro characterization and cytotoxicity

被引:115
作者
Memisoglu-Bilensoy, E [1 ]
Vural, L
Bochot, A
Renoir, JM
Duchene, D
Hincal, AA
机构
[1] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
[2] Univ Paris Sud, Fac Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France
关键词
tamoxifen curate; amphiphilic cyclodextrin; nanoparticle; characterization; cytotoxicity;
D O I
10.1016/j.jconrel.2005.03.006
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanospheres and nanocapsules of beta-CDC6, amphiphilic beta-cyclodextrin modified on the secondary face with 6C aliphatic esters, were prepared with nanoprecipitation technique directly from inclusion complexes of tamoxifen citrate and beta-CDC6 (1:1 molar ratio). Blank and loaded nanospheres and nanocapsules were characterized by particle size distribution, zeta potential, drug loading and in vitro drug release. Particle sizes were between 250 and 300 nm for different formulations of nanospheres and nanocapsules. Zeta potential which was around -18 mV for blank particles was reported to be between +12 and +15 mV for tamoxifen-loaded particles. Average entrapped drug quantity was found to be around 150 mu g/mL for particles prepared from inclusion complexes and this is double the loading value for conventionally prepared particles. Pre-loaded formulations showed a significantly slower release profile extended up to 6 h while formulations loaded conventionally displayed rapid and complete release within an hour. Cytotoxic efficacy of tamoxifen citrate loaded nanospheres and nanocapsules was determined against MCF-7 cells and tamoxifen citrate incorporated in amphiphilic p-cyclodextrin nanoparticles was found to be cytotoxic and effective against this cell line. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 23 条
[1]   Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation [J].
Brigger, I ;
Chaminade, P ;
Marsaud, V ;
Appel, M ;
Besnard, M ;
Gurny, R ;
Renoir, M ;
Couvreur, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 214 (1-2) :37-42
[2]   Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen [J].
Chawla, JS ;
Amiji, MM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 249 (1-2) :127-138
[3]   Endometrial pathologies associated with postmenopausal tamoxifen treatment [J].
Cohen, I .
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) :256-266
[4]   Effects of low dose tamoxifen on normal breast tissue from premenopausal women [J].
de Lima, GR ;
Facina, G ;
Shida, JY ;
Chein, MBC ;
Tanaka, P ;
Dardes, RC ;
Jordan, VC ;
Gebrim, LH .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (07) :891-898
[5]   Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins [J].
Dubes, A ;
Parrot-Lopez, H ;
Abdelwahed, W ;
Degobert, G ;
Fessi, H ;
Shahgaldian, P ;
Coleman, AW .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 55 (03) :279-282
[6]   Cyclodextrins and carrier systems [J].
Duchêne, D ;
Wouessidjewe, D ;
Ponchel, G .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :263-268
[7]   Cyclodextrins in targeting -: Application to nanoparticles [J].
Duchêne, D ;
Ponchel, G ;
Wouessidjewe, D .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (01) :29-40
[8]  
FESSI H, 1988, Patent No. 5118529
[9]   Influence of chemical structure of amphiphilic β-cyclodextrins on their ability to form stable nanoparticles [J].
Gèze, A ;
Aous, S ;
Baussanne, I ;
Putaux, JL ;
Defaye, J ;
Wouessidjewe, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 242 (1-2) :301-305
[10]  
HINCAL AA, 2003, B TECH GATTEFOSSE, V96, P35